Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
A delay in treatment of>or =3 months does not appear to affect adversely biochemical recurrence-free survival in patients who undergo definitive therapy for clinically localized prostate cancer in those with low risk features.
This is the first study to show the therapeutic efficacy of the local delivery of imatinib mesylate using a polymeric delivery system.